ArticleFrontiers in immunology2023

Cost-effectiveness analysis of serplulimab plus chemotherapy in the first-line treatment for PD-L1-positive esophageal squamous cell carcinoma in China.

Shixian Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.